CN102961392A - Application of Rg1 in preparation of drug for treating metabolic disorders caused by drinking - Google Patents
Application of Rg1 in preparation of drug for treating metabolic disorders caused by drinking Download PDFInfo
- Publication number
- CN102961392A CN102961392A CN2012104403534A CN201210440353A CN102961392A CN 102961392 A CN102961392 A CN 102961392A CN 2012104403534 A CN2012104403534 A CN 2012104403534A CN 201210440353 A CN201210440353 A CN 201210440353A CN 102961392 A CN102961392 A CN 102961392A
- Authority
- CN
- China
- Prior art keywords
- drinking
- preparation
- ginsenoside
- raises
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to application of ginsenoside Rg1 in preparation of a drug for treating or improving metabolic disorders and related diseases caused by drinking. In a single-time drinking experiment, by the Rg1, triglyceride content in the blood can be obviously reduced; and in a heavy drinking model, the survival rate of drinking mice can be obviously improved, blood serum glutamic-pyruvic transaminase and glutamic oxalacetic transaminase contents are reduced, the contents of the cholesterol and triglyceride in the blood are reduced and the like.
Description
Technical field
The present invention relates to the ginsenoside Rg1 in preparation treatment or improve application in the preparation that causes metabolism disorder and relevant disease of drinking.
Background technology
Drinking to cause that the body intracellular metabolite is disorderly, causes a series of disease and occurs, and main manifestations can improve diabetes, hyperlipidemia, hypertensive sickness rate for drinking, thereby promotes the generation of metabolism syndrome.Metabolic syndrome mainly comprises high triglyceride (TG) mass formed by blood stasis and low hdl-hypercholesterolemia take lipid metabolic disorder as core content.Drinking can stimulate the acid of fatty tissue release fat and very low density lipoprotein (VLDL) (VLDL) and Chylomicron removing speed from blood are slowed down, therefore excessive drinking can increase Diagnostic Value of Fasting Serum TG and low density lipoprotein, LDL (LDL) level, thereby causes the disorderly symptoms such as triglyceride in the blood, cholesterol level increase.
Except affecting lipid metabolism, drink and to cause multiple visceral organ injury, for example the metabolite acetaldehyde of ethanol can cause vascular endothelial cell damage, produce leukocyte infiltration, the inflammatory reactions such as inflammatory factor release increases, in blood biochemistry checking, show as the transaminase and raise, comprise the rising of glutamic oxaloacetic transaminase, GOT, glutamate pyruvate transaminase and Dehydrogenase Content.Inflammatory reaction can affect organ function, and biochemical analysis shows as creatinine, and bilirubin, Determination of Bile Acids change.Except the variation of above-mentioned biochemical indicator, heavy drinking can increase alcohol user's mortality rate.
The above-mentioned metabolism disorder and the disease that cause for drinking, clinical treatment mostly is symptomatic treatment, increasing the weight of by the alleviating alcohol addiction mitigate the disease for example, improve immunity of organisms by nutrition supporting therapy, for the patient with severe symptoms, often give glucocorticoid and improve the short-term survival rate, and with hemodialysis as assisting the deficiency that remedies renal function.Yet above-mentioned treatment means all is difficult to the therapeutic effect that reaches desirable.Therefore, seek a kind of safe and reliable can treating metabolism disorder and relevant disease medicine that causes of drinking and to produce important meaning.
The ginsenoside Rg1 belongs to protopanaxatriol ginsenoside, is one of total active component of panax species.It has defying age, improves immunity of organisms, promotes the effects such as learning and memory, there is no so far report but treat Developmental and Metabolic Disorder and the relevant disease thereof that causes of drinking about the ginsenoside Rg1.
Summary of the invention
For better treatment or improve Developmental and Metabolic Disorder and the relevant disease thereof of drinking and causing, the invention provides the ginsenoside Rg1 in the preparation treatment or improve application in the preparation that causes metabolism disorder and relevant disease thereof of drinking.
Treatment of the present invention or improvement are drunk and are caused the preparation of metabolism disorder and relevant disease thereof, both can be medicines, also can be health product and other any dosage forms; Both can be that the treatment relevant disease is purpose, also can be to improve or prevention drinks that to cause metabolism disorder be purpose.Said preparation can be the ginsenoside Rg1 of single component, also can be ginsenoside Rg1 and other compound preparation that becomes to be grouped into, and wherein the ginsenoside Rg1 is as main component or non-main component.
Ginsenoside Rg1 of the present invention can be isolated by extractions such as Radix Ginseng, Radix Notoginseng or Radix Panacis Quinquefoliis, perhaps chemosynthesis and getting.Specifically, described ginsenoside Rg1 can by root, stem and/or the leaf of Radix Ginseng, Radix Notoginseng or Radix Panacis Quinquefolii, utilize the process extraction of prior art to be isolated.
The present invention relates to the ginsenoside Rg1 in preparation treatment or improve application in the preparation that causes metabolism disorder and relevant disease thereof of drinking.
Described drinking causes metabolism disorder to refer to: the transaminase raises in the blood, triglyceride raises, cholesterol raises, lactic acid dehydrogenase raises, serum creatinine raises, bile acid raises or bilirubin raises.
Described relevant disease refers to: alcoholic fatty liver, alcoholic hepatitis, alcoholic cardiomyopathy and the cholecystitis that causes by drinking, renal failure etc.
Described preparation is oral formulations or ejection preparation.Described oral formulations comprises tablet, capsule, granule, pill, drop, fruit juice agent, syrup and containing agent etc.; Described injection comprises injectable powder and liquid injection etc.
The useful technique effect that invention realizes comprises at least:
During single was drunk and tested, Rg1 can significantly reduce the content of triglyceride in the blood; In the heavy drinking model, Rg1 can significantly improve the mice survival rate of drinking, and reduces glutamate pyruvate transaminase and glutamic oxaloacetic transaminase, GOT content in the serum, reduces blood cholesterol, the content of triglyceride etc.
The specific embodiment
Below enumerating embodiment specifies ginsenoside Rg1 involved in the present invention in preparation treatment or improves application in the preparation that causes metabolism disorder and relevant disease thereof of drinking.But the present invention is not limited to following embodiment.
The curative effect that the present invention observes the ginsenoside Rg1 by the model of drinking of setting up different pathological stages.Research adopts the C57 mice as the object of observation, is divided into single drink metabolism disorder and the metabolism disorder model of repeatedly drinking, and observation index comprises mice survival rate, the interior transaminase activity of serum, lipoprotein content etc.
Embodiment 1: the ginsenoside Rg1 is to the drink protective effect of metabolism disorder mice of single
1. materials and methods
1.1 animal: male and healthy C57 mice (20-22g), available from laboratory animal resource center of National Institute for Food and Drugs Control, the quality certification number (SCXK (capital) 2009-0017), animal feeding is in cleaning level Animal House, and ad lib is drunk water.Adapt to and begin to test after three days.
1.2 medicine and instrument: the ginsenoside Rg1 (purity〉95%, the extremely pure bio tech ltd in Yunnan provides), ethanol (Red Star strong, colourless liquor distilled from sorghum 56%), Hitachi automatic clinical chemistry analyzer (Japan), triglyceride (TG) detection kit is available from the middle north control bio tech ltd of giving birth to.
1.3 the medicinal liquid preparation: the ginsenoside Rg1 is dissolved in the distilled water, and concentration is respectively 4mg/ml, and 2mg/ml and 1mg/ml, administration volume are the 10ml/kg body weight.
1.4 animal grouping and processing: 75 mices are divided into 5 groups at random, every group of 15 mices comprise blank group, model group, Rg1 organizes (10mg Rg1/kg body weight, 20mg Rg1/kg body weight, 40mg Rg1/kg body weight), except the blank group, all mices are the oral ethanol that gives all, ethanol (conversion is 100%) dosage is 6g/kg, and the mice rear ginsenoside Rg1 (oral) who gave corresponding dosage in 1 hour that drinks gets blood and carries out biochemical analysis after 12 hours.
1.5 blood parameters detects: adopt the eye socket blood taking method to collect blood, carry out centrifugal (3000 rev/mins) under room temperature, it is to be measured that the collection supernatant is stored in-80 ℃ of refrigerators.Triglyceride detects the adhere rigidly to test kit and requires to carry out.
Statistical analysis: all data all represent with mean ± standard deviation, adopt SPSS13.0 to carry out one factor analysis of variance, take P＜0.05 as the significant difference standard.
Experimental result
The ginsenoside Rg1 can reduce the drink rising of content of triglyceride in the blood that causes of single.
Lipid metabolism is one of the modal metabolism disorder performance that causes of drinking unusually.This research finds that the ginsenoside Rg1 can significantly reduce the rising of the Triglycerides in Serum content that causes owing to drinking, and illustrates that the ginsenoside Rg1 has the ability (seeing Table 1) of the fat metabolic disturbance that improving drinks causes.
Table 1: the impact of triglyceride in the blood that the ginsenoside Rg1 causes drinking
The blank group of ##:P＜0.01VS, *: P＜0.05, * *: P＜0.01VS model group.
Embodiment 2: the ginsenoside Rg1 is to serious symptom the drink metabolism disorder that causes and the protective effect of relevant disease thereof
1.1 animal: male and healthy C57 mice (20-22g), available from laboratory animal resource center of National Institute for Food and Drugs Control, the quality certification number (SCXK (capital) 2009-0017), animal feeding is in cleaning level Animal House, and ad lib is drunk water.Adapt to and begin to test after three days.
1.2 medicine and instrument: the ginsenoside Rg1 (purity〉95%, the extremely pure bio tech ltd in Yunnan provides), ethanol (Red Star strong, colourless liquor distilled from sorghum 56%) Hitachi automatic clinical chemistry analyzer (Japan), the glutamate pyruvate transaminase test kit, the glutamic oxaloacetic transaminase, GOT test kit, the lactic dehydrogenase enzyme reagent kit, the Triglyceride Reagent box, Cholesterol Kit, the low density lipoprotein, LDL test kit, high density lipoprotein test kit, bilirubin reagent box, bile acid test kit, creatinine reagent box are all available from the middle north control bio tech ltd of giving birth to.
2. animal grouping and processing: 50 mices are divided into 5 groups at random, and every group of 10 mices comprise blank group, model group, Rg1 organizes (10mg Rg1/kg body weight, 20mg Rg1/kg body weight, 40mg Rg1/kg body weight), except the blank group, all mice oral ethanol every day once, ethanol (conversion is 100%) dosage is 6g/kg, 1 hour gavage gives corresponding medicine after the administration, successive administration 5 days was got blood in 1 hour and is carried out biochemical analysis after the last administration.
3. blood parameters detects: mice 1 hour employing eye socket blood taking method after the last administration is collected blood, carries out centrifugal (3000 rev/mins) under room temperature, and it is to be measured that the collection supernatant is stored in-80 ℃ of refrigerators.Blood parameters detects and comprises glutamic oxaloacetic transaminase, GOT in the serum, glutamate pyruvate transaminase, lactic acid dehydrogenase, cholesterol, triglyceride, low density lipoprotein, LDL, high density lipoprotein, bile acid, and bilirubin and creatinine, experimental implementation adhere rigidly to test kit require to carry out.
Statistical analysis: all data all represent with mean ± standard deviation, adopt SPSS13.0 to carry out one factor analysis of variance, take P＜0.05 as the significant difference standard.
Experimental result
The ginsenoside Rg1 is on the impact of heavy drinking mice survival rate
The heavy drinking mortality rate is high, this result of study shows that survival rate is 30% in the severe Alcoholic damage mice 5 days, survival rate significantly promotes after the Rg1 treatment, Rg1 10mg/kg, the survival rate of 20mg/kg and 40mg/kg is respectively 60%, 80% and 90%, show that the ginsenoside Rg1 can significantly promote the reduction (seeing Table 2) of the mice survival rate that heavy drinking causes.
The impact of the survival rate that table 2 ginsenoside Rg1 causes drinking
The ginsenoside Rg1 is to the analysis of heavy drinking mice serum biochemical indicator
Heavy drinking can cause the dysfunction of the multiple organ of body; in blood parameters, show as the rising of glutamate pyruvate transaminase, glutamic oxaloacetic transaminase, GOT and lactic acid dehydrogenase equal size; the ginsenoside Rg1 can significantly reduce the content (seeing Table 3) of glutamate pyruvate transaminase, glutamic oxaloacetic transaminase, GOT and lactic acid dehydrogenase in the rear blood of drinking, and the prompting ginsenoside Rg1 has protective effect to the organ dysfunction that heavy drinking causes.
The impact of the blood parameters that table 3. ginsenoside Rg1 causes drinking
#:P＜0.05, the blank group of ##:P＜0.01VS, *: P＜0.05, * *: P＜0.01VS model group.
The ginsenoside Rg1 is on the impact of fat and cholesterol level in the heavy drinking mice serum
Heavy drinking can cause that lipid metabolism is unusual, and modal triglyceride in the blood, cholesterol and the low density lipoprotein, LDL content of showing as raises.This result of study shows that triglyceride, cholesterol and low density lipoprotein, LDL content all are significantly higher than blank group in the heavy drinking mice serum, and there is abnormalities of sugar/lipid metabolism in the prompting mice.The ginsenoside Rg1 can significantly reduce the triglyceride that causes by drinking, the content of cholesterol and low density lipoprotein, LDL, but to hdl concentration do not make significant difference (seeing Table 4).
The impact of the lipid metabolic disorder that table 4 ginsenoside Rg1 causes heavy drinking
The blank group of ##:P＜0.01VS, *: P＜0.05, * *: P＜0.01VS model group.
The ginsenoside Rg1 is on the impact of heavy drinking mice serum mesobilirubin, bile acid and creatinine content
Heavy drinking can cause digestion and renal system dysfunction, shows as the rising of blood mesobilirubin, bile acid and creatinine content.This result of study shows that three's content all is significantly higher than blank group in the heavy drinking mice serum, and the ginsenoside Rg1 can significantly reduce the rising of the bilirubin, bile acid and the creatinine content that cause by drinking.
The impact of the bilirubin that table 5. ginsenoside Rg1 causes heavy drinking, bile acid and creatinine content
The blank group of ##:P＜0.01VS, *: P＜0.05, * *: P＜0.01VS model group.
Obviously, those skilled in the art can carry out various changes and modification to the present invention and not break away from the spirit and scope of the present invention.Like this, if of the present invention these are revised and modification belongs within the scope of claim of the present invention and equivalent technologies thereof, then the present invention also is intended to comprise these changes and modification interior.
Claims (4)
1. the ginsenoside Rg1 is in preparation treatment or improve application in the preparation that causes metabolism disorder and relevant disease thereof of drinking.
2. the described application of claim 1 is characterized in that, described drinking causes metabolism disorder to refer to that the transaminase raises in the blood, triglyceride raises, cholesterol raises, lactic acid dehydrogenase raises, serum creatinine raises, bile acid raises or bilirubin raises.
3. the described application of claim 1 is characterized in that, described relevant disease refers to: alcoholic fatty liver, alcoholic hepatitis, alcoholic cardiomyopathy and the cholecystitis that causes by drinking, renal failure etc.
4. the described application of claim 1 is characterized in that, described preparation is oral formulations or ejection preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012104403534A CN102961392A (en) | 2012-11-07 | 2012-11-07 | Application of Rg1 in preparation of drug for treating metabolic disorders caused by drinking |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012104403534A CN102961392A (en) | 2012-11-07 | 2012-11-07 | Application of Rg1 in preparation of drug for treating metabolic disorders caused by drinking |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410565911.9A Division CN104382916A (en) | 2012-11-07 | 2012-11-07 | Application of Rg1 to preparation of bile acid rise treating preparation |
| CN201410565934.XA Division CN104382917A (en) | 2012-11-07 | 2012-11-07 | Application of Rg1 to preparation of bilirubin rising treating preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102961392A true CN102961392A (en) | 2013-03-13 |
Family
ID=47792011
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012104403534A Pending CN102961392A (en) | 2012-11-07 | 2012-11-07 | Application of Rg1 in preparation of drug for treating metabolic disorders caused by drinking |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102961392A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103550589A (en) * | 2013-11-09 | 2014-02-05 | 刘立敏 | Pharmaceutical composition for treating alcoholic cardiomyopathy arrhythmia |
| CN108096262A (en) * | 2018-02-05 | 2018-06-01 | 重庆医科大学 | Application of the ginsenoside Rg1 in the drug for preparing treatment fatty liver |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1887316A (en) * | 2005-06-29 | 2007-01-03 | 上海师范大学 | Chinese medicine composition and its prepn process and application |
| CN101810659A (en) * | 2010-05-20 | 2010-08-25 | 吉林省抚松制药股份有限公司 | Total saponins of salvia chinensis benth, and medical application and preparation method thereof |
-
2012
- 2012-11-07 CN CN2012104403534A patent/CN102961392A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1887316A (en) * | 2005-06-29 | 2007-01-03 | 上海师范大学 | Chinese medicine composition and its prepn process and application |
| CN101810659A (en) * | 2010-05-20 | 2010-08-25 | 吉林省抚松制药股份有限公司 | Total saponins of salvia chinensis benth, and medical application and preparation method thereof |
Non-Patent Citations (3)
| Title |
|---|
| 潘玉芳，等: "三七皂苷rg1抗疲劳和耐缺氧作用的研究", 《临床和实验医学杂志》, vol. 5, no. 8, 30 August 2006 (2006-08-30), pages 1120 - 1121 * |
| 裴晋红，等: "三七皂甙Rg1、Rb1抗大鼠纤维化的作用以及作用机制的研究", 《齐齐哈尔医学院学报》, vol. 32, no. 7, 31 December 2011 (2011-12-31), pages 1025 - 1026 * |
| 马岚清，等: "人参皂苷Rg1抗纤维化的实验研究", 《中国中西医结合消化杂志》, vol. 15, no. 3, 30 June 2007 (2007-06-30), pages 165 - 168 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103550589A (en) * | 2013-11-09 | 2014-02-05 | 刘立敏 | Pharmaceutical composition for treating alcoholic cardiomyopathy arrhythmia |
| CN108096262A (en) * | 2018-02-05 | 2018-06-01 | 重庆医科大学 | Application of the ginsenoside Rg1 in the drug for preparing treatment fatty liver |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102038720B (en) | Inonotus obliquus blood sugar-reducing effective part and preparation method and application thereof | |
| CN104705258B (en) | A kind of construction method of diet induced insulin resistant model and application | |
| CN105169096B (en) | A kind of pharmaceutical composition for treating gout or/and hyperuricemia | |
| CN107050148A (en) | A kind of Chinese medicinal composition for dispelling drunk and protecting liver and its preparation method and preparation method thereof | |
| CN109985086B (en) | Cyclocarya paliurus leaf instant powder and preparation method thereof | |
| CN104435034A (en) | PNS (panax notoginseng saponins) and preparation method thereof | |
| CN102961392A (en) | Application of Rg1 in preparation of drug for treating metabolic disorders caused by drinking | |
| CN102068557B (en) | Application of Pu'er tea extract in preparation of medicines for reducing blood fat | |
| CN101879162A (en) | Weight-losing medicament formed by matching alpha-ricinoleic acid ethyl ester with berberine | |
| CN109045070A (en) | A kind of composition for preventing and treating non-alcoholic fatty liver disease | |
| WO2013159751A1 (en) | Pharmaceutical composition, preparation method and use thereof | |
| CN101554406B (en) | Extraction process and formulation of mulberry cortex hypoglycemic medicinal active material | |
| CN101744844A (en) | Fulvic acid or sodium fulvate substance with hypoglycemic function | |
| CN101444599B (en) | Corn silk extract and preparation method thereof and application thereof in preparing drugs for treating gout | |
| CN101816719B (en) | Peach blossom or peach leaf general flavone and application thereof in preparing medicines or health care products for lowering blood sugar and fat and preventing and/or treating diabetes and complications | |
| CN108498590B (en) | A natural hypoglycemic agent for improving bioavailability and preventing hyperchloremia | |
| CN104382917A (en) | Application of Rg1 to preparation of bilirubin rising treating preparation | |
| CN104382916A (en) | Application of Rg1 to preparation of bile acid rise treating preparation | |
| CN101822683A (en) | Medical care application of L-arabinose composition | |
| CN105535152B (en) | Application of loquat leaf total sesquiterpene extract | |
| CN101559069A (en) | Application of 5' nucleotide in preparation of medicines and health-care foods for alleviating physical fatigue | |
| CN102028703B (en) | New application of inulin | |
| CN105193886A (en) | Preparation method and medical application of blood-fat-reducing active component | |
| CN103989835A (en) | Composition for reducing blood sugar, decreasing blood fat and protecting liver and preparation method and application thereof | |
| CN110123824B (en) | Ilicis Pubescentis saponin A1New use of |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20130313 |